Pemetrexed and cisplatin for advanced soft tissue cancer
Part of Cancer clinical trials.
This Phase 2 trial tests whether pemetrexed plus cisplatin can shrink advanced or metastatic soft tissue sarcoma. It may help people whose cancer has spread and who can safely receive chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older, and you have advanced or metastatic soft tissue sarcoma confirmed by biopsy
- Your cancer has measurable spots that can be tracked on scans (measurable disease)
- Your body is strong enough for treatment (performance status 0 or 1)
- Your blood tests and organ function (kidneys, liver, and blood counts) are adequate to take chemotherapy
- You are not currently pregnant: either postmenopausal, or if able to become pregnant you have a negative pregnancy test
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining seed radiation (iodine-125 placed in/near the tumor) with fluzoparib can better control advanced, hard-to-remove soft tissue sarcoma. It may help shrink tumors and slow progression, but you must meet several cancer, health, and safety requirements.
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
This Phase 2 trial tests pazopanib alone or together with pembrolizumab to slow or shrink metastatic soft-tissue sarcoma after prior chemotherapy. It may help some people by strengthening the anti-cancer effect compared with pazopanib by itself.
This Phase 1/2 trial tests whether combining radiation with two targeted/immune medicines can shrink or control high-risk soft tissue sarcoma and improve outcomes. It may help patients whose tumors are large, hard to fully remove, or have come back after prior treatment.
This trial tests a new immunotherapy drug (envafolimab) combined with two chemotherapy drugs (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior treatment. The goal is to see if this combination is safe and effective.
This trial tests whether a type of chemotherapy called pegylated liposomal doxorubicin (PLD) can help keep advanced soft tissue sarcoma from growing after successful first treatment with standard anthracycline-based chemo. You may be eligible if you've completed 4-8 cycles of that initial chemo and your disease is controlled (shrank or stable).
Hear when a new Sarcoma,Soft Tissue trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.